Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Revenue (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Revenue for 14 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 26.4% year-over-year to $1.4 million, compared with a TTM value of $6.6 million through Dec 2025, down 51.24%, and an annual FY2025 reading of $6.6 million, down 51.24% over the prior year.
  • Revenue was $1.4 million for Q4 2025 at Fate Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Revenue topped out at $59.0 million in Q1 2023 and bottomed at $933000.0 in Q2 2023.
  • Average Revenue over 5 years is $11.8 million, with a median of $4.9 million recorded in 2024.
  • Peak annual rise in Revenue hit 625.83% in 2024, while the deepest fall reached 96.74% in 2024.
  • Year by year, Revenue stood at $17.1 million in 2021, then soared by 159.86% to $44.4 million in 2022, then crashed by 96.22% to $1.7 million in 2023, then rose by 10.98% to $1.9 million in 2024, then dropped by 26.4% to $1.4 million in 2025.
  • Business Quant data shows Revenue for FATE at $1.4 million in Q4 2025, $1.7 million in Q3 2025, and $1.9 million in Q2 2025.